Intracerebral transplantation of genetically engineered cells for Parkinson's disease: Toward clinical application

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Over the last decade, molecular biology has progressively developed, leading to new technology with subsequent clinical application for various cerebral diseases including Parkinson's disease (PD), one of the most investigated neurodegenerative disorders. The therapy for PD is mainly composed of medication, including drug replacement therapy, surgical treatment, and cell transplantation. Cell therapy for PD has been explored by using fetal nigral cells as an alio- or xenograft, autologous sympathetic ganglion, adrenal medulla, and carotid body in clinical settings. In addition, neurotrophic factors, including glial cell line-derived neurotrophic factor (GDNF), have a strong potency to rescue degenerating dopaminergic cells. Protein and/or gene therapy also might be a therapeutic option for PD. In this review, genetically engineered cell transplantation for animal models of PD, including catecholamine/neurotrophic factor-secreting cell transplantation with or without encapsulation, as performed in our laboratories, and their potential future as clinical applications are described with recent clinical studies in this field.

Original languageEnglish
Pages (from-to)125-132
Number of pages8
JournalCell Transplantation
Volume16
Issue number2
Publication statusPublished - 2007

Fingerprint

Parkinson Disease
Transplantation
Cell Transplantation
Nerve Growth Factors
Glial Cell Line-Derived Neurotrophic Factor
Carotid Body
Sympathetic Ganglia
Adrenal Medulla
Gene therapy
Substantia Nigra
Cell- and Tissue-Based Therapy
Molecular biology
Heterografts
Neurodegenerative Diseases
Genetic Therapy
Catecholamines
Molecular Biology
Encapsulation
Therapeutics
Animal Models

Keywords

  • Encapsulation
  • GDNF
  • Parkinson's disease
  • Stem cell
  • Tet-off
  • VEGF

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation

Cite this

@article{1a08f8458ab34763be8e382296590ccd,
title = "Intracerebral transplantation of genetically engineered cells for Parkinson's disease: Toward clinical application",
abstract = "Over the last decade, molecular biology has progressively developed, leading to new technology with subsequent clinical application for various cerebral diseases including Parkinson's disease (PD), one of the most investigated neurodegenerative disorders. The therapy for PD is mainly composed of medication, including drug replacement therapy, surgical treatment, and cell transplantation. Cell therapy for PD has been explored by using fetal nigral cells as an alio- or xenograft, autologous sympathetic ganglion, adrenal medulla, and carotid body in clinical settings. In addition, neurotrophic factors, including glial cell line-derived neurotrophic factor (GDNF), have a strong potency to rescue degenerating dopaminergic cells. Protein and/or gene therapy also might be a therapeutic option for PD. In this review, genetically engineered cell transplantation for animal models of PD, including catecholamine/neurotrophic factor-secreting cell transplantation with or without encapsulation, as performed in our laboratories, and their potential future as clinical applications are described with recent clinical studies in this field.",
keywords = "Encapsulation, GDNF, Parkinson's disease, Stem cell, Tet-off, VEGF",
author = "Takao Yasuhara and Isao Date",
year = "2007",
language = "English",
volume = "16",
pages = "125--132",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "2",

}

TY - JOUR

T1 - Intracerebral transplantation of genetically engineered cells for Parkinson's disease

T2 - Toward clinical application

AU - Yasuhara, Takao

AU - Date, Isao

PY - 2007

Y1 - 2007

N2 - Over the last decade, molecular biology has progressively developed, leading to new technology with subsequent clinical application for various cerebral diseases including Parkinson's disease (PD), one of the most investigated neurodegenerative disorders. The therapy for PD is mainly composed of medication, including drug replacement therapy, surgical treatment, and cell transplantation. Cell therapy for PD has been explored by using fetal nigral cells as an alio- or xenograft, autologous sympathetic ganglion, adrenal medulla, and carotid body in clinical settings. In addition, neurotrophic factors, including glial cell line-derived neurotrophic factor (GDNF), have a strong potency to rescue degenerating dopaminergic cells. Protein and/or gene therapy also might be a therapeutic option for PD. In this review, genetically engineered cell transplantation for animal models of PD, including catecholamine/neurotrophic factor-secreting cell transplantation with or without encapsulation, as performed in our laboratories, and their potential future as clinical applications are described with recent clinical studies in this field.

AB - Over the last decade, molecular biology has progressively developed, leading to new technology with subsequent clinical application for various cerebral diseases including Parkinson's disease (PD), one of the most investigated neurodegenerative disorders. The therapy for PD is mainly composed of medication, including drug replacement therapy, surgical treatment, and cell transplantation. Cell therapy for PD has been explored by using fetal nigral cells as an alio- or xenograft, autologous sympathetic ganglion, adrenal medulla, and carotid body in clinical settings. In addition, neurotrophic factors, including glial cell line-derived neurotrophic factor (GDNF), have a strong potency to rescue degenerating dopaminergic cells. Protein and/or gene therapy also might be a therapeutic option for PD. In this review, genetically engineered cell transplantation for animal models of PD, including catecholamine/neurotrophic factor-secreting cell transplantation with or without encapsulation, as performed in our laboratories, and their potential future as clinical applications are described with recent clinical studies in this field.

KW - Encapsulation

KW - GDNF

KW - Parkinson's disease

KW - Stem cell

KW - Tet-off

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=34247579230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247579230&partnerID=8YFLogxK

M3 - Article

C2 - 17474294

AN - SCOPUS:34247579230

VL - 16

SP - 125

EP - 132

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 2

ER -